The Neuroscience Report—Vol. 15 (August 10, 2015): Antipsychotic Medications

| August 10, 2015 | 0 Comments

Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks.

Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information.


Volume 15 (August 10, 2015): Antipsychotic Medications


Journal Articles

Rationale for Iloperidone in the Treatment of Posttraumatic Stress Disorder

Pseudoephedrine for the Treatment of Clozapine-Induced Incontinence

Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method

The Role of Long-acting Injectable Antipsychotics in Schizophrenia: A Critical Appraisal

The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review


 

News Articles

Positive Preclinical Results and Patent Allowed for Aequus’ Once-Weekly Transdermal Aripiprazole

Otsuka, Lundbeck bag blockbuster FDA approval for antipsychotic Rexulti

Antipsychotic Use Rising Among Teens and Young Adults

New Analysis of Smoking and Schizophrenia Suggests Causal Link

FDA Approves Invega Trinza, Four-times-a-year Treatment for Schizophrenia


Wildcards

Quantifying Clinical Relevance

Summer and Antipsychotics in the City

A History of the Ice Pick Lobotomy

Anything to Avoid the Pain

 


Have a “supafly” week!

Supafly

 

Tags: ,

Category: Psychiatry, Psychopharmacology, Schizophrenia, The Neuroscience Report

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.